Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

Edwin Wong; Carla Nester; Teresa Cavero; Alexandre Karras; Moglie Le Quintrec; Liz Lightstone; Ute Eisenberger; María José Soler; David Kavanagh; Erica Daina; Manuel Praga; Nicholas Medjeral‐Thomas; Anja Gäckler; Clara García-Carro; Andrea Biondani; Frédérique Chaperon; Kenneth Kulmatycki; Julie Milojevic; Nicholas J.A. Webb; Prasanna Kumar Nidamarthy; G. Junge; Giuseppe Remuzzi

doi:10.1016/j.ekir.2023.09.017

Related publications

Article2024

#277 Update to the long-term safety and efficacy of iptacopan in C3G: 33-month extension study data from patients enrolled in a phase 2 study

Carla Nester, Ute Eisenberger, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, María José Soler Romeo, Junhao Liu, Matthias Meier, Nicholas J.A. Webb, Edwin Wong

Article2021

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

Edwin Wong, Manuel Praga, Carla Nester, Moglie Le Quintrec, Erica Daina, Giuseppe Remuzzi, Angelo J. Trapani, Yaqin Wang, Junhao Liu, G. Junge, Matthias Meier, Nicholas J.A. Webb

Article2025

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

Marina Vivarelli, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri

Article2025

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher,

Article2025

#3018 Iptacopan's rapid and sustained inhibition of overactive complement alternative pathway in C3G: Exploratory analysis from the Phase 3 APPEAR-C3G study

Erica Daina, Giuseppe Remuzzi, David Kavanagh, Imelda Schuhmann, Rubeen Israni, Hari Kalluri, Deborah Keefe, Yaqin Wang, Junhao Liu, Aiko P. J. de Vries

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

Abstract

Discussion(0)

Related publications

#277 Update to the long-term safety and efficacy of iptacopan in C3G: 33-month extension study data from patients enrolled in a phase 2 study

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

#3018 Iptacopan's rapid and sustained inhibition of overactive complement alternative pathway in C3G: Exploratory analysis from the Phase 3 APPEAR-C3G study